Cargando…

Commentary on Composite cognitive and functional measures for early stage Alzheimer's disease trials

Detalles Bibliográficos
Autores principales:	Rentz, Dorene M., Papp, Kathryn V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7819348/ https://www.ncbi.nlm.nih.gov/pubmed/33521233 http://dx.doi.org/10.1002/dad2.12012

Ejemplares similares

Commentary: Composite cognitive and functional measures for early stage Alzheimer's disease trials
por: Harrison, John E.
Publicado: (2020)

Optimizing the preclinical Alzheimer's cognitive composite with semantic processing: The PACC5
por: Papp, Kathryn V., et al.
Publicado: (2017)

Response to peer commentaries: Composite cognitive and functional measures for early stage Alzheimer's disease trials
por: Schneider, Lon S., et al.
Publicado: (2020)

Composite cognitive and functional measures for early stage Alzheimer's disease trials
por: Schneider, Lon S., et al.
Publicado: (2020)

Computerized cognitive practice effects in relation to amyloid and tau in preclinical Alzheimer's disease: Results from a multi‐site cohort
por: Young, Christina B., et al.
Publicado: (2023)

Response to Schneider and Goldberg “Composite cognitive and functional measures for early stage Alzheimer's disease trials”
por: Sano, Mary, et al.
Publicado: (2020)

Validating Use of Technology for Cognitive Test Assessment
por: Rentz, Dorene M.
Publicado: (2016)

Relation of modifiable lifestyle and mood factors to cognitive concerns among participants and their study partners in the A4 screen data
por: Reynolds, Gretchen, et al.
Publicado: (2023)

Face Name Associative Memory Exam and biomarker status in the ARMADA study: Advancing reliable measurement in Alzheimer's disease and cognitive aging
por: Rentz, Dorene M., et al.
Publicado: (2023)

Monthly At-Home Computerized Cognitive Testing to Detect Diminished Practice Effects in Preclinical Alzheimer's Disease
por: Jutten, Roos J., et al.
Publicado: (2022)

The Computerized Cognitive Composite (C3) in A4, an Alzheimer’s Disease Secondary Prevention Trial
por: Papp, K.V., et al.
Publicado: (2021)

Unsupervised mobile cognitive testing for use in preclinical Alzheimer's disease
por: Papp, Kathryn V., et al.
Publicado: (2021)

Diminished Learning Over Repeated Exposures (LORE) in preclinical Alzheimer's disease
por: Samaroo, Aubryn, et al.
Publicado: (2021)

Costs of Early Stage Alzheimer’s Disease in the United States: Cross-Sectional Analysis of a Prospective Cohort Study (GERAS-US)(1)
por: Robinson, Rebecca L., et al.
Publicado: (2020)

Neuroimaging correlates of Stages of Objective Memory Impairment (SOMI) system
por: Grober, Ellen, et al.
Publicado: (2021)

The Latin American Spanish version of the Face-Name Associative Memory Exam is sensitive to cognitive and pathological changes in preclinical autosomal dominant Alzheimer’s disease
por: Vila-Castelar, Clara, et al.
Publicado: (2020)

Integrated Alzheimer's Disease Rating Scale: Clinically meaningful change estimates
por: Wessels, Alette M., et al.
Publicado: (2022)

Measuring cognition and function in the preclinical stage of Alzheimer's disease
por: Weintraub, Sandra, et al.
Publicado: (2018)

Associations of Stages of Objective Memory Impairment With Amyloid PET and Structural MRI: The A4 Study
por: Grober, Ellen, et al.
Publicado: (2022)

Decreased meta-memory is associated with early tauopathy in cognitively unimpaired older adults
por: Vannini, Patrizia, et al.
Publicado: (2019)

Longitudinal Trajectories of Participant- and Study Partner-Rated Cognitive Decline, in Relation to Alzheimer’s Disease Biomarkers and Mood Symptoms
por: Munro, Catherine E., et al.
Publicado: (2022)

Disparities by Race and Ethnicity Among Adults Recruited for a Preclinical Alzheimer Disease Trial
por: Raman, Rema, et al.
Publicado: (2021)

Promising developments in neuropsychological approaches for the detection of preclinical Alzheimer’s disease: a selective review
por: Rentz, Dorene M, et al.
Publicado: (2013)

Inferior and medial temporal tau and cortical amyloid are associated with daily functional impairment in Alzheimer’s disease
por: Halawa, Omar A., et al.
Publicado: (2019)

Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease: A Longitudinal Study
por: Hanseeuw, Bernard J., et al.
Publicado: (2019)

Decline in cognitively complex everyday activities accelerates along the Alzheimer’s disease continuum
por: Dubbelman, Mark A., et al.
Publicado: (2020)

Composite neurocognitive endpoints in Alzheimer's disease clinical trials: A commentary
por: Randolph, Christopher
Publicado: (2020)

Device-Embedded Cameras for Eye Tracking–Based Cognitive Assessment: Validation With Paper-Pencil and Computerized Cognitive Composites
por: Bott, Nicholas, et al.
Publicado: (2018)

A computerized version of the Short Form of the Face-Name Associative Memory Exam (FACEmemory®) for the early detection of Alzheimer’s disease
por: Alegret, Montserrat, et al.
Publicado: (2020)

Current advances in digital cognitive assessment for preclinical Alzheimer's disease
por: Öhman, Fredrik, et al.
Publicado: (2021)

Observation of Patient and Caregiver Burden Associated with Early Alzheimer’s Disease in the United States: Design and Baseline Findings of the GERAS-US Cohort Study(1)
por: Robinson, Rebecca L., et al.
Publicado: (2019)

Cognitive rehabilitation for elderly people with early-stage Alzheimer’s disease
por: Kim, Seyun
Publicado: (2015)

A novel cognitive-functional composite measure to detect changes in early Alzheimer's disease: Test–retest reliability and feasibility
por: Jutten, Roos J., et al.
Publicado: (2017)

Lower novelty-related locus coeruleus function is associated with Aβ-related cognitive decline in clinically healthy individuals
por: Prokopiou, Prokopis C., et al.
Publicado: (2022)

A composite measure of cognitive and functional progression in Alzheimer's disease: Design of the Capturing Changes in Cognition study
por: Jutten, Roos J., et al.
Publicado: (2017)

Multiple markers contribute to risk of progression from normal to mild cognitive impairment
por: Rabin, Jennifer S., et al.
Publicado: (2020)

Automatized FACEmemory® scoring is related to Alzheimer’s disease phenotype and biomarkers in early-onset mild cognitive impairment: the BIOFACE cohort
por: Alegret, Montserrat, et al.
Publicado: (2022)

Everyday cognition scales are related to cognitive function in the early stage of probable Alzheimer’s disease and FDG-PET findings
por: Hsu, Jung-Lung, et al.
Publicado: (2017)

Early-stage Alzheimer disease: getting trial-ready
por: Aisen, Paul S., et al.
Publicado: (2022)

Demonstration of Clinical Meaningfulness of the Integrated Alzheimer’s Disease Rating Scale (iADRS): Association Between Change in iADRS Scores and Patient and Caregiver Health Outcomes
por: Wessels, Alette M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_76ivhkgqptp7plgt3gj19g28ej